In the field of tumor research, the process by which E3 ubiquitin ligases specifically ubiquitinate substrate proteins and promote their degradation has garnered significant attention. DTX3L, an emerging E3 ubiquitin ligase of the Deltex family, is closely associated with the development and progression of various malignant tumors. Through multiple mechanisms such as epigenetic modifications, signal pathway activation, and protein interaction networks, DTX3L precisely regulates key biological processes, including cell proliferation, cycle progression, migration, invasion, and apoptosis. This review systematically summarizes cutting-edge research findings on DTX3L across numerous malignant tumors and analyzes its regulatory mechanisms and functional manifestations in these cancers. From a clinical translation perspective, DTX3L, with its unique substrate selectivity, is becoming a promising cancer therapeutic target. However, therapeutic strategies targeting DTX3L require more in-depth and thorough validation for clinical translation. In summary, DTX3L is expected to serve as a crucial bridge connecting basic research with clinical applications, playing a significant role in cancer precision diagnosis and treatment.
Mu et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: